Winston Pharmaceuticals, Inc. (WPHM.OB) Receives SBIR Grant from the National Institutes of Health (NIH) to Investigate Treatment for Postherpetic Neuralgia of the Trigeminal Nerve  
4/9/2012 9:50:52 AM

VERNON HILLS, Ill.--(BUSINESS WIRE)--Winston Pharmaceuticals, Inc. (“Winston”), a specialty pharmaceutical company focused on developing and commercializing novel pain management therapies, announced that the National Institutes of Health (NIH) has awarded Winston a grant under the Small Business Innovation Research (SBIR) program supporting the development of Civamide, a proprietary TRPV-1 receptor modulator, for the treatment of postherpetic neuralgia (PHN) of the trigeminal nerve (TN). The Phase I award in the amount of approximately $375,000 will be administered by the National Institute of Neurological Disorders and Stroke (NINDS).